Sign In
Buy OABI
OmniAb Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0600 |
| EPS Surprise | 40.00% |
| Revenue estimate | 5.6M |
| Revenue actual | 14.427M |
| Revenue Surprise | 157.63% |
| Release date | Mar 04, 2026 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.110 |
| EPS Surprise | -37.50% |
| Revenue estimate | 9.003M |
| Revenue actual | 8.376M |
| Revenue Surprise | -6.97% |
| Release date | Nov 04, 2025 |
| EPS estimate | -$0.136 |
| EPS actual | -$0.140 |
| EPS Surprise | -2.94% |
| Revenue estimate | 5.644M |
| Revenue actual | 2.239M |
| Revenue Surprise | -60.33% |
| Release date | Aug 06, 2025 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.150 |
| EPS Surprise | -7.14% |
| Revenue estimate | 5.644M |
| Revenue actual | 3.897M |
| Revenue Surprise | -30.95% |
Last 4 Quarters for OmniAb
Below you can see how OABI performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 06, 2025 |
| Price on release | $1.93 |
| EPS estimate | -$0.140 |
| EPS actual | -$0.150 |
| EPS surprise | -7.14% |
| Date | Price |
|---|---|
| Jul 31, 2025 | $1.91 |
| Aug 01, 2025 | $1.91 |
| Aug 04, 2025 | $1.95 |
| Aug 05, 2025 | $2.04 |
| Aug 06, 2025 | $1.93 |
| Aug 07, 2025 | $1.88 |
| Aug 08, 2025 | $1.97 |
| Aug 11, 2025 | $1.96 |
| Aug 12, 2025 | $1.96 |
| 4 days before | 1.05% |
| 4 days after | 1.55% |
| On release day | -2.59% |
| Change in period | 2.62% |
| Release date | Nov 04, 2025 |
| Price on release | $1.48 |
| EPS estimate | -$0.136 |
| EPS actual | -$0.140 |
| EPS surprise | -2.94% |
| Date | Price |
|---|---|
| Oct 29, 2025 | $1.47 |
| Oct 30, 2025 | $1.49 |
| Oct 31, 2025 | $1.55 |
| Nov 03, 2025 | $1.48 |
| Nov 04, 2025 | $1.48 |
| Nov 05, 2025 | $1.43 |
| Nov 06, 2025 | $1.38 |
| Nov 07, 2025 | $1.38 |
| Nov 10, 2025 | $1.49 |
| 4 days before | 0.680% |
| 4 days after | 0.676% |
| On release day | -3.72% |
| Change in period | 1.36% |
| Release date | Mar 04, 2026 |
| Price on release | $1.81 |
| EPS estimate | -$0.0800 |
| EPS actual | -$0.110 |
| EPS surprise | -37.50% |
| Date | Price |
|---|---|
| Feb 26, 2026 | $1.80 |
| Feb 27, 2026 | $1.72 |
| Mar 02, 2026 | $1.76 |
| Mar 03, 2026 | $1.73 |
| Mar 04, 2026 | $1.81 |
| Mar 05, 2026 | $2.00 |
| Mar 06, 2026 | $1.89 |
| Mar 09, 2026 | $1.95 |
| Mar 10, 2026 | $1.99 |
| 4 days before | 0.556% |
| 4 days after | 9.94% |
| On release day | 10.50% |
| Change in period | 10.56% |
| Release date | May 07, 2026 |
| Price on release | $1.47 |
| EPS estimate | -$0.100 |
| EPS actual | -$0.0600 |
| EPS surprise | 40.00% |
| Date | Price |
|---|---|
| May 01, 2026 | $1.40 |
| May 04, 2026 | $1.41 |
| May 05, 2026 | $1.40 |
| May 06, 2026 | $1.43 |
| May 07, 2026 | $1.47 |
| May 08, 2026 | $1.66 |
| May 11, 2026 | $1.67 |
| May 12, 2026 | $1.85 |
| May 13, 2026 | $2.01 |
| 4 days before | 5.00% |
| 4 days after | 36.73% |
| On release day | 12.93% |
| Change in period | 43.57% |
OmniAb Earnings Call Transcript Summary of Q1 2026
OmniAb reported a strong start to 2026 driven by partner program progress and milestones. Key operational highlights include 107 active partners and 409 active programs (98% with contracted future economics), 32 active clinical programs/approved products, and continued adoption of new technologies—most notably OmniUltra (transgenic chicken producing ultra-long CDRH3 antibodies) and OmnidAb (single-domain antibodies). xPloration, a high-throughput single B-cell screening platform, is gaining traction as an instrument/consumables revenue opportunity. Financially, Q1 revenue was $14.4M (vs. $4.2M YoY), primarily milestone-driven; GAAP operating expenses were $22.3M (including a $2.9M noncash write-off). Net loss was $7.7M ($0.06/sh), improved vs. prior year. Management raised full-year 2026 revenue guidance to $28M–$33M, maintained cash operating expense guidance at $50M–$55M, and now expects year-end cash of $33M–$38M. Upcoming catalysts include multiple partner clinical readouts in 2026 (notably Teva's TEV-408 vitiligo data in H1 and several ASCO presentations). Management expects AI/ML demand and expanded target discovery to be long-term tailwinds for their data-rich platforms.
